摘要
目的:探讨trastuzumab联合卡铂(CBP)对过表达Her-2/neu的食管癌细胞增殖的抑制作用.方法:常规培养食管癌细胞株EC109及TE3,采用流式细胞仪筛选出高表达Her-2/neu的食管癌细胞株EC109;将对数期生长的食管癌EC109细胞分为trastuzumab治疗组、CBP治疗组以及trastu-zumab联合CBP治疗组,分别采用不同工作浓度的trastuzum-ab、CBP以及trastuzumab联合CBP对相应实验组的EC109细胞给药,MTT法检测各组药物在不同工作浓度时对食管癌EC109细胞增殖抑制率,AnnexinV/PI双染色法检测肿瘤细胞凋亡率.结果:Trastuzumab单药、CBP单药或Trastuzumab联合CBP均能有效抑制EC109细胞的增殖,其抑制效应呈剂量依赖性(P<0.05),当药物工作浓度≥1PPC(血浆峰浓度,PPC)时,Trastuzumab联合CBP对EC109细胞的增殖抑制效应明显强于Trastuzumab单药组或CBP单药组,差异有统计学意义(P<0.05).Trastuzumab单药或CBP单药均能诱导EC109细胞凋亡,当药物工作浓度≥1PPC时,Trastuzumab联合CBP诱导的EC109细胞平均凋亡率明显高于Trastuzumab单药组或CBP单药组,差异有统计学意义(P<0.05).结论:Trastuzumab与卡铂联合应用具有协同效应,可以有效地抑制过表达Her-2/neu的食管癌EC109细胞增殖,诱导肿瘤细胞凋亡.
AIM：To investigate the antiproliferative effect of trastuzumab combined with carboplatin on her-2/neu-overexpressing esophageal carcinoma cells. METHODS：The esophageal carcinoma cell lines EC109 and TE3 were cultured routinely. The expression of her-2/neu of these cell lines was examined by flow cytometry and EC109 cells with her-2/neu-overexpressing were selected to be further studied. The EC109 cells in logarithmic phase were distributed into 3 groups. The first group was treated by trastuzumab alone,the second by carboplatin alone and the third by trastuzumab combined with earboplatin. Each group then was further distributed into 5 subgroups, which were incubated with different doses of above mentioned drugs respectively. MTY assay was performed to observe the inhibitory effects of each dose of each medication, and apoptosis in EC109 ceils of each subgroup was measured by Annexin-V/PI assay. RESULTS：The dose-dependent inhibitory effects on EC109 cells with her-2/neu- overexpressing was observed among all 3 groups （ P 〈 0.05 ）, but the group treated by combined drugs exhibited a significantly greater inhibitory effect on cell growth than any single drug when the drug dose was larger than 1PPC （ plasma peak concentration of drug） （P 〈0.05）. The apoptosis in EC109 cells of each group was also noted with an observation of significantly higher apoptosis-inducing activity of combined treatment than that of trastuzumab alone or earboplatin alone when the drug dose was larger than 1PPC （ P 〈 0.05 ）. CONCLUSION： The combination oftrastuzumab and carboplatin could produce synergistically antipro- liferative and apoptosis-inducing effects on her-2/neu-overexpressing esophageal carcinoma EC109 cells.
出处
《第四军医大学学报》
北大核心
2009年第21期2285-2288,共4页
Journal of the Fourth Military Medical University
基金
云南省教育厅资助项目(08C0111)
